Stoke Therapeutics (NASDAQ:STOK) has received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price target of $39.00 for the company and are anticipating that the company will post ($1.02) EPS for the current quarter, according to Zacks. Zacks has also given Stoke Therapeutics an industry rank of 51 out of 256 based on the ratings given to related companies.
Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. reissued a “sell” rating and set a $18.00 price objective on shares of ABB in a research report on Monday, July 15th. Canaccord Genuity assumed coverage on Slack in a research report on Monday, July 15th. They set a “buy” rating and a $40.00 price objective for the company. Credit Suisse Group set a $5.00 price objective on Maxar Technologies and gave the stock a “sell” rating in a research report on Monday, July 15th. Finally, Cowen reissued a “buy” rating on shares of Avrobio in a research report on Monday, July 15th.
Shares of NASDAQ STOK traded down $0.74 during trading hours on Wednesday, hitting $22.71. 1,746 shares of the company’s stock were exchanged, compared to its average volume of 182,725. Stoke Therapeutics has a 1-year low of $22.84 and a 1-year high of $31.76.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Read More: What is a Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.